Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 2/23/18 → 2/23/24 |
Funding
- CTI Clinical Trial and Consulting Services (Prot #VT3996-201 // Prot #VT3996-201)
- Viracta Therapeutics, Inc. (Prot #VT3996-201 // Prot #VT3996-201)
Prot #VT3996-201: A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies
- Karmali, Reem (PD/PI)
Project: Research project